SynKIR-310 for Relapsed/Refractory B-NHL

Part of paid clinical trials in Denver, Colorado.

Sponsor
Verismo Therapeutics
Study ID
NCT06544265
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • B Cell Lymphoma
  • DLBCL
  • DLBCL (Diffuse Large B-Cell Lymphoma) Associated With Chronic Inflammation
  • DLBCL - Diffuse Large B Cell Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Epstein-Barr Virus Positive DLBCL, Nos
  • Follicular Lymphoma
  • Follicular Lymphoma Grade 3
  • Follicular Lymphoma Grade 3B
  • HGBL With MYC and BCL2 and/or BCL6 Rearrangements
  • High Grade B-Cell Lymphoma, Not Otherwise Specified
  • High-grade B-cell Lymphoma
  • Indolent B-Cell Non-Hodgkin Lymphoma
  • Large B-cell Lymphoma
  • Mantle Cell Lymphoma
  • Marginal Zone Lymphoma
  • Marginal Zone Splenic Lymphoma
  • NHL, Adult
  • Non-hodgkin Lymphoma,B Cell
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • Refractory Non-Hodgkin Lymphoma
  • Relapsed Non-Hodgkin Lymphoma
  • T-Cell/Histiocyte Rich Lymphoma
  • Waldenstrom Macroglobulinaemia
  • Waldenstrom Macroglobulinemia

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • SynKIR-310 — BIOLOGICAL
    Autologous T Cells transduced with CD19 KIR-CAR

Study Details

This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.

Key Dates

Start date
Nov 1, 2024
Status verified
Apr 2026
Primary completion
Sep 30, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
36 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SynKIR-310
    Single dose IV administration of SynKIR-310

Primary Outcome Measure

Evaluate the safety of SynKIR310 [ Time Frame: Up to 24 months ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
Colorado Blood Cancer Institute, part of Sarah Cannon Cancer InstituteDenverColorado80218
Cicelia Veloz
[email protected]
720-754-8068
Autumn Wagner
[email protected]
720-754-8068
Michael T. Tees, MD (PRINCIPAL_INVESTIGATOR)
Winship Cancer Institute of Emory UniversityAtlantaGeorgia30322
Molly Stoddart
[email protected]
404-778-6547
Edmund Waller, MD, PhD (PRINCIPAL_INVESTIGATOR)
The University of Kansas Cancer CenterFairwayKansas66205
Nurse Navigator
[email protected]
913-945-7552
Joseph McGuirk, DO (PRINCIPAL_INVESTIGATOR)
Rutgers Cancer InstituteNew BrunswickNew Jersey08902
Hem/Onc Clinical Trial Lab Manager
[email protected]
732-235-7315
Matthew Matasar, MD (PRINCIPAL_INVESTIGATOR)
Abramson Cancer Center of the University of PennsylvaniaPhiladelphiaPennsylvania19104
Brittany Koch
[email protected]
215-776-5548
Stephen Schuster, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Denver, CO

By research site
Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute· Denver, COWinship Cancer Institute of Emory University· Atlanta, GAThe University of Kansas Cancer Center· Fairway, KSRutgers Cancer Institute· New Brunswick, NJAbramson Cancer Center of the University of Pennsylvania· Philadelphia, PA

Related Studies